Allogenetics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Series A
  • (In Progress)

  • Investors
  • 6

Allogenetics General Information

Description

Developer of an ex vivo gene therapy platform intended to eliminate organ rejection in transplant patients by genetically modifying donor organs to render them immunologically invisible to the recipient's immune system. The company's platform applies viral transduction during organ perfusion to deactivate tissue markers that trigger rejection, enabling transplant patients and centers to eliminate the need for lifelong immunosuppression and improve long-term graft survival.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Feodor-Lynen-Straße 5
  • Lower Saxony
  • 30625 Hannover
  • Germany
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Feodor-Lynen-Straße 5
  • Lower Saxony
  • 30625 Hannover
  • Germany

Allogenetics Timeline

2023202420252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Allogenetics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC (Series A) 14-Sep-2026 In Progress Clinical Trials - Phase 1
5. Early Stage VC 09-Sep-2026 Completed Clinical Trials - Phase 1
4. Early Stage VC 30-Aug-2024 Completed Clinical Trials - Phase 1
3. Early Stage VC 01-Aug-2024 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Jan-2023 Completed Startup
1. University Spin-Out 07-Sep-2022 Completed Startup
To view Allogenetics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Allogenetics Patents

Allogenetics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3994264-A1 Tissue for use as allogeneic or xenogeneic transplant and method for its production Pending 04-Jul-2019
US-20230010683-A1 Tissue for use as allogeneic or xenogeneic transplant and method for its production Pending 04-Jul-2019
AU-2018274161-A1 Method for genetically modifying a vascularised tissue Active 26-May-2017
AU-2018274161-B2 Method for genetically modifying a vascularised tissue Active 26-May-2017 A01N1/126

Allogenetics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Allogenetics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Life Science Valley Ventures Management Venture Capital Minority
Ascenion Accelerator/Incubator Minority
CARMA FUND Management Venture Capital Minority
NBank Capital Venture Capital Minority
BioIntelligence Accelerator/Incubator Minority
You’re viewing 5 of 6 investors. Get the full list »

Allogenetics FAQs

  • When was Allogenetics founded?

    Allogenetics was founded in 2022.

  • Where is Allogenetics headquartered?

    Allogenetics is headquartered in Hannover, Germany.

  • What is the size of Allogenetics?

    Allogenetics has 17 total employees.

  • What industry is Allogenetics in?

    Allogenetics’s primary industry is Drug Discovery.

  • Is Allogenetics a private or public company?

    Allogenetics is a Private company.

  • What is Allogenetics’s current revenue?

    The current revenue for Allogenetics is .

  • How much funding has Allogenetics raised over time?

    Allogenetics has raised $11.8M.

  • Who are Allogenetics’s investors?

    Life Science Valley Ventures Management, Ascenion, CARMA FUND Management, NBank Capital, and BioIntelligence are 5 of 6 investors who have invested in Allogenetics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process